In October we reported the good news that the National Institute for Health and Care Excellence (NICE) had provisionally approved enzalutamide, a life-extending cancer drug, for men with advanced prostate cancer who have stopped responding to hormone therapy and chemotherapy. However, today NICE has revised that draft decision, and says that enzalutamide should only be made available post chemotherapy to those men who haven’t already been treated with abiraterone – the only other available treatment for men at this stage of the disease.

Read more

TeamPB

A team of runners sporting retro 1970s y-fronts, Georgian corsets and bright sequinned bras sprinted through central London this morning, encouraging fellow runners to join TeamPB for the Virgin London Marathon this April.

Read more